Compare · DXCM vs INO
DXCM vs INO
Side-by-side comparison of DexCom Inc. (DXCM) and Inovio Pharmaceuticals Inc. (INO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and INO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.89B, about 274.3x INO ($105.3M).
- Over the past year, DXCM is down 12.5% and INO is down 38.8% - DXCM leads by 26.4 points.
- DXCM has been more active in the news (29 items in the past 4 weeks vs 22 for INO).
- DXCM has more recent analyst coverage (25 ratings vs 13 for INO).
- Company
- DexCom Inc.
- Inovio Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $28.89B
- $105.3M
- 1M return
- +25.76%
- +14.22%
- 1Y return
- -12.46%
- -38.81%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 29
- 22
- Recent ratings
- 25
- 13
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Latest DXCM
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)
- Director Gala Renee D was granted 5,605 shares, increasing direct ownership by 81% to 12,486 units (SEC Form 4)
Latest INO
- INOVIO to Participate in Upcoming Scientific and Investor Conferences
- SEC Form 4 filed by Director Yarno Wendy L
- SEC Form 4 filed by Director Shepard Jay
- SEC Form 4 filed by Director Miller Ann Calby
- SEC Form 4 filed by Director Weiner David B.
- SEC Form 4 filed by Director Zoth Lota S.
- SEC Form 4 filed by Director Dansey Roger D
- SEC Form 4 filed by Director Benito Simon X
- Chief Scientific Officer Humeau Laurent converted options into 6,027 shares and covered exercise/tax liability with 2,163 shares, increasing direct ownership by 9% to 46,823 units (SEC Form 4) (for withholding tax)
- Chief Medical Officer Sumner Michael John converted options into 9,450 shares and covered exercise/tax liability with 2,693 shares, increasing direct ownership by 19% to 42,038 units (SEC Form 4) (for tax liability)